Neogenomics (NEO) Long-Term Investments (2020 - 2021)

Neogenomics' (NEO) quarterly Long-Term Investments came in at $29.6 million in Q1 2021, little changed on a QoQ basis from $29.6 million in Q4 2020.

Neogenomics (NEO) Long-Term Investments (2020 - 2021) Analysis & Trends

Neogenomics (NEO) has 2 years of Long-Term Investments data on file, last reported at $29.6 million in Q1 2021.

Quarterly Long-Term Investments changed N/A year-over-year to $29.6 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $29.6 million (changed N/A YoY) and the FY2020 annual result came in at $29.6 million, changed N/A from the prior year.
Long-Term Investments was little changed at $29.6 million in Q1 2021, from $29.6 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $29.6 million in Q4 2020 to a low of $13.1 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Thermo Fisher Scientific	213.44 Bn	209.37 Bn	8.34 Bn	-
2	Danaher	139.95 Bn	135.60 Bn	3.61 Bn	-
3	Idexx Laboratories	46.16 Bn	45.96 Bn	779.09 Mn	-
4	Agilent Technologies	39.67 Bn	37.87 Bn	990.00 Mn	136.00 Mn
5	Iqvia Holdings	39.29 Bn	37.21 Bn	1.44 Bn	390.00 Mn
6	Natera	38.61 Bn	37.51 Bn	696.04 Mn	-
7	Illumina	29.99 Bn	28.82 Bn	770.00 Mn	-
8	Mettler Toledo International	28.57 Bn	28.51 Bn	650.22 Mn	-
9	Quest Diagnostics	26.17 Bn	25.55 Bn	1.03 Bn	137.00 Mn
10	Neogenomics	2.04 Bn	1.89 Bn	91.88 Mn	-

Download Data